Index
Letters b, f, and t after page numbers indicate box, figure, and table, respectively.
Academy of Nutrition and Dietetics, 1–2 acetate, 36b, 38–39, 83b acid-base balance, 38–39 acidosis, metabolic, 38, 39, 78, 78b additives, 44–45 advance directives, 111 advancing parenteral nutrition, 58, 59b air embolism, 23, 106b alanine aminotransferase, 57t, 108b alkaline phosphatase levels, 57t, 108b alkalosis, metabolic, 38, 39 allergic reactions, 35–36, 69 alternate sites, parenteral nutrition in, 87–111 aluminum, 43–44, 81 accuracy of label information on, 43–44, 81, 83b and bone disease, 77, 78b as contaminant, 44, 81 in long-term therapy, 83b toxicity of, 43–44, 78b, 81 American Medical Association, 40, 41 American Society for Parenteral and Enteral Nutrition (ASPEN) on branched chain amino acids, 33 on formula prescription calculations, 49 on glucose levels, 60
on glutamine supplementation, 44 on indications for parenteral nutrition, 5 on multi-chamber bag parenteral nutrition, 50
on peripheral parenteral nutrition, 9 on product shortages, 45, 46 on refeeding syndrome, 64 American Society of Health- System Pharmacists, 45, 46 amino acids, 32–34 in formula prescription calculations, 49b in hepatic formulas, 33
124
in long-term parenteral nutrition, 82b, 84b in metabolic bone disease, 77, 78b in osmolarity calculation, 16b in renal formulas, 33–34 in 3-in-1 preparations, 48, 49b in 2-in-1 preparations, 46, 49b
anaphylaxis, 69 anthropometric measurements in nutrition assessment, 55, 56 appropriate use of parenteral nutrition, 5–11
aromatic amino acids, 33 arterial injury in central catheter placement, 23b
ascites, 11, 56 ascorbic acid (vitamin C), 40, 41b, 83b aseptic technique, 28, 98, 100f, 105 aspartate aminotransferase, 57t, 108b ASPEN. See American Society for Parenteral and Enteral Nutrition
assessment for parenteral nutrition, 1–11 in home parenteral nutrition, 93, 109 in long-term parenteral nutrition, 79, 80 parameters in, 55–56 physical examination in, 56
Association of Gastrointestinal Motility Disorders, 107
automated compounding devices, 46 azotemia, 8b
bacterial infections bloodstream, 26–27 local, 25–26
bacterial overgrowth, 68, 74b, 76b, 78 bariatric surgery, 6b, 10, 65b barrier precautions in central line insertion, 27 basilic vein as access site, 14, 15f bicarbonate levels, 38, 39 bilirubin levels elevated, 67–68, 74, 81
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149
